Greg Madison, an experienced executive with specific knowledge about iron deficiency, has been appointed chief executive of Shield Therapeutics Plc, effective 1 June. Shield is making preparations for the launch of the iron deficiency product Accrufer in the US. Mr Madison joins Shield from Melt Pharmaceuticals Inc in the US where he was also CEO. Earlier in his career, he worked at Genzyme Corp (now part of Sanofi SA) where he managed the company’s nephrology division.
Shield Therapeutics announced the appointment on 28 May 2021.
Copyright 2021 Evernow Publishing Ltd